Truncated (N)-Methanocarba Nucleosides as Al Adenosine Receptor Agonists and Partial Agonists: Receptor Docking and Potent Anticonvulsant Activity for the Treatment of Various Conditions

This technology includes A1AR-selective agonists which are full or partial agonists of the A1AR and are being considered for treatment of various conditions: seizures, stroke, diabetes, pain, cardio-protection and arrhythmias. A1AR agonists are highly neuroprotective in ischemic and epileptic models. A1AR agonists are also being explored for antidepressant, antianxiety, and other neuropsychiatric effects, due to their presynaptic action to decrease the release of excitatory amino acids in the brain. However, peripheral cardiovascular side effects have prevented the introduction of A1AR agonist for treating disorders of the central nervous system (CNS).